Diligence memo · auto-generated · as of July 2, 2026
DTx Pharma, Inc.
DTx Pharma, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
DTx Pharma, Inc. operates in Pharmaceuticals, based in SAN DIEGO.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
DTx Pharma, Inc. has raised $113M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $100M on 2021-02-26.
Most recent recorded round closed around 2021-02-26.
Valuation (modeled)modeled
Provath models DTx Pharma, Inc. at approximately $2.9B (range $477M–$5.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.79× the median modeled value of Series D+ Pharmaceuticals companies in 2019–2021 (15 peers) — value vs value, same stage and era. Within the normal band (79% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 11 months.
Last raise 5.3 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 501.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 92% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 97% of those peers.
Closest niche peers: Nuvation Bio Inc., Recursion Pharmaceuticals, Inc., Vyripharm Enterprises, Inc., Verona Pharma plc, Cingulate Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.